Nanobiotix (NASDAQ:NBTX) Shares Gap Down – Should You Sell?

Nanobiotix S.A. – Sponsored ADR (NASDAQ:NBTX – Get Free Report)’s share price gapped down prior to trading on Tuesday. The stock had previously closed at $30.66, but opened at $27.90. Nanobiotix shares last traded at $27.36, with a volume of 7,020 shares.

Analyst Ratings Changes

A number of analysts have recently weighed in on the company. Weiss Ratings restated a “sell (d-)” rating on shares of Nanobiotix in a research note on Thursday, October 15th. Guggenheim assumed coverage on Nanobiotix in a report on Tuesday, September 15th. They issued a “buy” rating and a $64.00 price target for the company. Four equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, Nanobiotix currently has a consensus rating of “Moderate Buy” and a consensus target price of $46.67.

Get Our Latest Stock Report on Nanobiotix

Nanobiotix Stock Performance

The stock’s fifty day moving average is $29.72 and its 200-day moving average is $34.29.

Hedge Funds Weigh In On Nanobiotix

A hedge fund recently bought a new stake in Nanobiotix stock. Aquatic Capital Management LLC purchased a new stake in Nanobiotix S.A. – Sponsored ADR (NASDAQ:NBTX – Free Report) during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 2,118 shares of the company’s stock, valued at approximately $66,000. 38.81% of the stock is owned by hedge funds and other institutional investors.

About Nanobiotix

(Get Free Report)

Nanobiotix is a French biotechnology company developing nanoparticle-based treatments for cancer. Founded in 2003, the company focuses on using nanomedicine to enhance the effects of established cancer therapies, particularly radiation therapy. Its lead product candidate, NBTXR3, is made from hafnium oxide nanoparticles and is designed to be injected directly into a tumor. When exposed to radiation, the particles are intended to increase damage to cancer cells while limiting the effect on surrounding healthy tissue.

Further Reading

Receive News & Ratings for Nanobiotix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nanobiotix and related companies with MarketBeat.com's FREE daily email newsletter.